Science News
from research organizations

Bone metastases treatment can improve overall survival

Date:
November 15, 2012
Source:
International Association for the Study of Lung Cancer
Summary:
One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer developing bone loss. A study shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid.
Share:
       
FULL STORY

It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss. A study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid (ZA).

A total of 811 lung cancer patients (411 for denosumab and 400 for ZA) were evaluated. Patients were randomized 1:1 to receive either monthly subcutaneous injection of denosumab 120 mg (plus intravenous infusion of placebo) or monthly intravenous infusion of ZA 4 mg (plus subcutaneous injection of placebo). The ZA dose was adjusted for renal impairment. And, daily calcium and vitamin D supple¬mentation was strongly recommended for all patients.

In all 811 lung cancer patients, denosumab was associated with significally improved overall median survival compared with ZA, with a difference of 1.2 month. In patients with NSCLC, denosumab was associated with significant improved survival, with a difference of 1.5 months.

In addition, overall survival in patients with small-cell lung cancer was 7.6 months for the deno-sumab group and 5.1 months for the ZA group, a difference of 2.5 months. Denosumab-treated patients with squamous cell carcinoma also showed improved survival compared with the ZA group, with a difference of 2.2 months. The treatments were associated with similar overall survival in patients with adenocarcinoma.


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Bone metastases treatment can improve overall survival." ScienceDaily. ScienceDaily, 15 November 2012. <www.sciencedaily.com/releases/2012/11/121115141625.htm>.
International Association for the Study of Lung Cancer. (2012, November 15). Bone metastases treatment can improve overall survival. ScienceDaily. Retrieved May 28, 2015 from www.sciencedaily.com/releases/2012/11/121115141625.htm
International Association for the Study of Lung Cancer. "Bone metastases treatment can improve overall survival." ScienceDaily. www.sciencedaily.com/releases/2012/11/121115141625.htm (accessed May 28, 2015).

Share This Page: